JP4615805B2 - Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 - Google Patents

Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 Download PDF

Info

Publication number
JP4615805B2
JP4615805B2 JP2001538942A JP2001538942A JP4615805B2 JP 4615805 B2 JP4615805 B2 JP 4615805B2 JP 2001538942 A JP2001538942 A JP 2001538942A JP 2001538942 A JP2001538942 A JP 2001538942A JP 4615805 B2 JP4615805 B2 JP 4615805B2
Authority
JP
Japan
Prior art keywords
seq
isolated
cells
complex
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001538942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533175A (ja
JP2003533175A5 (enExample
Inventor
ベルモーリ、ダニーラ
セロッティーニ、ジャン−チャールズ
ロメロ、ペドロ
セルンドロ、ビンセンゾ
ロデリック ダンバー、ピーター
ジ−リ チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Cancer Research
Original Assignee
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/440,621 external-priority patent/US6417165B1/en
Priority claimed from US09/514,036 external-priority patent/US6689742B1/en
Priority claimed from US09/676,005 external-priority patent/US6605711B1/en
Application filed by Ludwig Cancer Research filed Critical Ludwig Cancer Research
Publication of JP2003533175A publication Critical patent/JP2003533175A/ja
Publication of JP2003533175A5 publication Critical patent/JP2003533175A5/ja
Application granted granted Critical
Publication of JP4615805B2 publication Critical patent/JP4615805B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001538942A 1999-11-15 2000-11-08 Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 Expired - Fee Related JP4615805B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/440,621 US6417165B1 (en) 1988-03-27 1999-11-15 NY-ESO-1-peptide derivatives, and uses thereof
US09/440,621 1999-11-15
US09/514,036 US6689742B1 (en) 2000-02-25 2000-02-25 NY-ESO-1 peptide derivatives, and uses thereof
US09/514,036 2000-02-25
US09/676,005 US6605711B1 (en) 1999-11-15 2000-09-29 NY-ESO-1 peptide derivatives, and uses thereof
US09/676,005 2000-09-29
PCT/US2000/042010 WO2001036453A2 (en) 1999-11-15 2000-11-08 Ny-eso-1 nanopeptide derivatives, and uses thereof

Publications (3)

Publication Number Publication Date
JP2003533175A JP2003533175A (ja) 2003-11-11
JP2003533175A5 JP2003533175A5 (enExample) 2006-12-21
JP4615805B2 true JP4615805B2 (ja) 2011-01-19

Family

ID=27412062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001538942A Expired - Fee Related JP4615805B2 (ja) 1999-11-15 2000-11-08 Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用

Country Status (5)

Country Link
EP (1) EP1230261B1 (enExample)
JP (1) JP4615805B2 (enExample)
AU (1) AU776058B2 (enExample)
CA (1) CA2390659C (enExample)
WO (1) WO2001036453A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923337D0 (en) * 1999-10-04 1999-12-08 Isis Innovation Binding agents
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
CN1910284B (zh) * 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20160017031A1 (en) * 2006-06-01 2016-01-21 Receptor Logic, LLC T cell receptor mimic rl9a
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP3676250A4 (en) * 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
CN112442118B (zh) * 2019-08-30 2023-02-14 深圳普瑞金生物药业股份有限公司 一种tcr及其应用
US20210369828A1 (en) * 2020-05-28 2021-12-02 Case Western Reserve University Plant virus based cancer antigen vaccine
WO2025171250A1 (en) * 2024-02-08 2025-08-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nyeso1 tcr for t-cell therapy and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Also Published As

Publication number Publication date
CA2390659A1 (en) 2001-05-25
CA2390659C (en) 2010-03-02
EP1230261B1 (en) 2008-06-25
AU3079101A (en) 2001-05-30
JP2003533175A (ja) 2003-11-11
WO2001036453A2 (en) 2001-05-25
EP1230261A2 (en) 2002-08-14
AU776058B2 (en) 2004-08-26
WO2001036453A3 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
ES2245783T3 (es) Dominio intracelular de la proteina her-2/neu para la prevencion o el tratamiento de neoplasias malignas.
JP4106179B2 (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−３ペプチド
JP4652390B2 (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ１ペプチド
JP4102027B2 (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ３ペプチド
ES2294844T3 (es) Peptidos antigenicos tumorales derivados de ciclofilina b.
US7049413B2 (en) MAGE-A3 peptides presented by HLA class II molecules
US6605711B1 (en) NY-ESO-1 peptide derivatives, and uses thereof
US20200157146A1 (en) Controlled modulation of amino acid side chain length of peptide antigens
US6710172B1 (en) Tumor antigens and CTL clones isolated by a novel procedure
US7311914B2 (en) MAGE-A4 antigenic peptides and uses thereof
EP1230261B1 (en) Ny-eso-1 nonapeptide derivatives, and uses thereof
US6417165B1 (en) NY-ESO-1-peptide derivatives, and uses thereof
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
KR20020047249A (ko) Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
US6689742B1 (en) NY-ESO-1 peptide derivatives, and uses thereof
EP0789591B1 (en) Methods for identifying individuals suffering from a cellular abnormality
US7041502B2 (en) Isolated peptides which bind to HLA-B18 molecules and uses thereof
JP2002536996A (ja) チロシンキナーゼ受容体ＥｐｈＡ３抗原ペプチド
US6680056B1 (en) Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of hla-cw 1601/mage-1 derived peptides, and methods for treating said individuals
WO2003104259A2 (en) PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF
HK1067645B (en) Tumor antigen peptides originating in cyclophilin b

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091009

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101014

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101021

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees